FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133606670> ?p ?o ?g. }

• W3133606670 endingPage "2207" @default.
• W3133606670 startingPage "2197" @default.
• W3133606670 abstract "Abstract BACKGROUND A new role as an antitumoral agent has been proposed for the local anesthetic bupivacaine (BVC), considering its toxic effects on cancer cells. However, such drug repositioning requires an improvement in drug available concentrations and sustained release profiles to surpass BVC short action and narrow therapeutic window. Nanostructured lipid carriers (NLC) may provide bupivacaine with sustained release, and they can be formulated with essential oils, whose intrinsic therapeutic properties may act synergistically with BVC. This study reports the development of two NLC formulations prepared with lavender or melaleuca oils and enantiomeric excess S (−)75: R (+)25 bupivacaine (BVC S75 ). The nanoparticles were characterized by dynamic light scattering, nanotracking analysis, transmission electron microscopy, differential scanning calorimetry and X‐ray diffraction, and their stability was followed for 1 year. Encapsulation efficiency and in vitro BVC S75 release profile were also measured. Additionally, the effect on the viability of mice (B16‐F10) and human (SK‐MEL‐25) melanoma cells was determined, as was in vivo anesthesia assessed by the tail flick test in mice. RESULTS The two formulations optimized by factorial design (NLC‐L‐B and NLC‐M‐B) showed robust physical and chemical properties, 1‐year stability and sustained release in vitro . Cytotoxicity tests revealed a decrease in IC 50 values, relative to free BVC S75 , of ~80% and 62% (NLC‐L‐B) and 80% and 25% (NLC‐M‐B) in mice and human melanoma cells, respectively. Encapsulation in both formulations doubled the anesthesia time of BVC S75 . CONCLUSION Combining the effects of bupivacaine and NLC excipients, the two optimized NLC formulations containing BVC S75 may be interesting nanosystems for the treatment of melanomas after further in vivo tests. © 2021 Society of Chemical Industry (SCI)." @default.
• W3133606670 created "2021-03-15" @default.
• W3133606670 creator A5001987797 @default.
• W3133606670 creator A5004981782 @default.
• W3133606670 creator A5011396094 @default.
• W3133606670 creator A5012201446 @default.
• W3133606670 creator A5013594393 @default.
• W3133606670 creator A5013870534 @default.
• W3133606670 creator A5051470064 @default.
• W3133606670 creator A5077139192 @default.
• W3133606670 creator A5087778101 @default.
• W3133606670 date "2021-03-17" @default.
• W3133606670 modified "2023-10-17" @default.
• W3133606670 title "Development of <scp> <i>S</i> 75 </scp> : <scp> <i>R</i> 25 </scp> bupivacaine‐loaded lipid nanoparticles functionalized with essential oils for treating melanoma" @default.
• W3133606670 cites W1606372310 @default.
• W3133606670 cites W1663319870 @default.
• W3133606670 cites W1969530011 @default.
• W3133606670 cites W1972545565 @default.
• W3133606670 cites W1976779766 @default.
• W3133606670 cites W1976903802 @default.
• W3133606670 cites W1991239422 @default.
• W3133606670 cites W1999166183 @default.
• W3133606670 cites W2005368506 @default.
• W3133606670 cites W2006897167 @default.
• W3133606670 cites W2011000945 @default.
• W3133606670 cites W2017734975 @default.
• W3133606670 cites W2020781268 @default.
• W3133606670 cites W2023942206 @default.
• W3133606670 cites W2027912711 @default.
• W3133606670 cites W2031656573 @default.
• W3133606670 cites W2035079262 @default.
• W3133606670 cites W2037414484 @default.
• W3133606670 cites W2045192573 @default.
• W3133606670 cites W2047465751 @default.
• W3133606670 cites W2049881401 @default.
• W3133606670 cites W2054189154 @default.
• W3133606670 cites W2054481098 @default.
• W3133606670 cites W2059669519 @default.
• W3133606670 cites W2060434868 @default.
• W3133606670 cites W2078738566 @default.
• W3133606670 cites W2078768792 @default.
• W3133606670 cites W2080854664 @default.
• W3133606670 cites W2085692671 @default.
• W3133606670 cites W2102109812 @default.
• W3133606670 cites W2114918609 @default.
• W3133606670 cites W2132187713 @default.
• W3133606670 cites W2140820226 @default.
• W3133606670 cites W2147575825 @default.
• W3133606670 cites W2149900156 @default.
• W3133606670 cites W2156102005 @default.
• W3133606670 cites W2162240885 @default.
• W3133606670 cites W2251624888 @default.
• W3133606670 cites W2345398159 @default.
• W3133606670 cites W2469208529 @default.
• W3133606670 cites W2516577345 @default.
• W3133606670 cites W2549976854 @default.
• W3133606670 cites W2566553562 @default.
• W3133606670 cites W2618512026 @default.
• W3133606670 cites W2622575134 @default.
• W3133606670 cites W2683554665 @default.
• W3133606670 cites W2738817946 @default.
• W3133606670 cites W2742978833 @default.
• W3133606670 cites W2769286742 @default.
• W3133606670 cites W2898146268 @default.
• W3133606670 cites W2900897110 @default.
• W3133606670 cites W2944081772 @default.
• W3133606670 cites W2949315527 @default.
• W3133606670 cites W2951804097 @default.
• W3133606670 cites W2966752580 @default.
• W3133606670 cites W2979391120 @default.
• W3133606670 cites W2997606439 @default.
• W3133606670 cites W3004982104 @default.
• W3133606670 cites W3006719128 @default.
• W3133606670 cites W3008547006 @default.
• W3133606670 cites W3009703853 @default.
• W3133606670 cites W3018018242 @default.
• W3133606670 cites W3030483011 @default.
• W3133606670 cites W3090832867 @default.
• W3133606670 cites W995588172 @default.
• W3133606670 doi "https://doi.org/10.1002/jctb.6715" @default.
• W3133606670 hasPublicationYear "2021" @default.
• W3133606670 type Work @default.
• W3133606670 sameAs 3133606670 @default.
• W3133606670 citedByCount "6" @default.
• W3133606670 countsByYear W31336066702021 @default.
• W3133606670 countsByYear W31336066702022 @default.
• W3133606670 countsByYear W31336066702023 @default.
• W3133606670 crossrefType "journal-article" @default.
• W3133606670 hasAuthorship W3133606670A5001987797 @default.
• W3133606670 hasAuthorship W3133606670A5004981782 @default.
• W3133606670 hasAuthorship W3133606670A5011396094 @default.
• W3133606670 hasAuthorship W3133606670A5012201446 @default.
• W3133606670 hasAuthorship W3133606670A5013594393 @default.
• W3133606670 hasAuthorship W3133606670A5013870534 @default.
• W3133606670 hasAuthorship W3133606670A5051470064 @default.
• W3133606670 hasAuthorship W3133606670A5077139192 @default.
• W3133606670 hasAuthorship W3133606670A5087778101 @default.
• W3133606670 hasConcept C109316439 @default.

• next